Allscripts Healthcare Stock
Your prediction
Pros and Cons of Allscripts Healthcare in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Allscripts Healthcare vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Allscripts Healthcare | - | - | - | - | - | - | - |
| Simulations Plus | -1.020% | -2.010% | -0.510% | -73.649% | -36.688% | -73.649% | -81.250% |
| Fonar Corp. New | 1.270% | 0.000% | 1.923% | 27.200% | 1.923% | 10.417% | 1.274% |
| MicroVision Inc | -9.930% | -6.046% | -21.148% | -52.534% | -25.559% | -73.572% | -95.099% |
Comments
Veradigm Inc. (NASDAQ: MDRX) had its price target lowered by analysts at TD Cowen from $26.00 to $15.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MDRX provided by MarketBeat
Veradigm Inc. (NASDAQ: MDRX) had its price target lowered by analysts at Royal Bank of Canada from $22.00 to $11.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for MDRX provided by MarketBeat